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Targeted covalent inhibitors represent a viable strategy to block protein kinases involved in different
disease pathologies. Although a number of computational protocols have been published for identifying
druggable cysteines, experimental approaches are limited for mapping the reactivity and accessibility of
these residues. Here, we present a ligand based approach using a toolbox of fragment-sized molecules
with identical scaffold but equipped with diverse covalent warheads. Our library represents a unique
opportunity for the efficient integration of warhead-optimization and target-validation into the covalent
drug development process. Screening this probe kit against multiple kinases could experimentally
characterize the accessibility and reactivity of the targeted cysteines and helped to identify suitable
warheads for designed covalent inhibitors. The usefulness of this approach has been confirmed retro-
spectively on Janus kinase 3 (JAK3). Furthermore, representing a prospective validation, we identified
Maternal embryonic leucine zipper kinase (MELK), as a tractable covalent target. Covalently labelling and
biochemical inhibition of MELK would suggest an alternative covalent strategy for MELK inhibitor
programs.
© 2020 The Author(s). Published by Elsevier Masson SAS. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Medicinal chemistry programs investigating covalent inhibitors
have come of age in the last decade [1,2]. Intensive targeted cova-
lent inhibitor (TCI) development in oncology has resulted in afatinib
(Gilotrif®) [3], an EGFR inhibitor that suppress the growth and
proliferation of tumor cells. It was a true milestone in cancer
therapy, and became the first FDA-approved covalent small-
molecule kinase inhibitor in 2013. Covalent small-molecule ki-
nase inhibitors represent a target-specific subtype of TCIs. Kinases
are one of the major classes of signaling proteins that trigger a
variety of biochemical processes (e.g. modulating enzyme activity,
changing protein conformation, increasing or decreasing stability,
activating protein functions) through their phosphorylation [4].
Kinase signaling pathways are involved in various diseases, like
immune disorders, cardiovascular andmetabolic diseases andmost
importantly a large number of different cancers [5,6]. Consequently,}u).
er Masson SAS. This is an open accethere has been a high demand for the design and development of
kinase inhibitors, particularly in the field of oncology [7]. Over the
past few years, approximately 40 kinases have been pursued as
potential targets [8], but only few targeted covalent inhibitors have
received FDA approval: e.g. afatinib [3] (Gilotrif®), osimertinib [9]
(Tagrisso®), neratinib [10] (Nerlynx®) and dacomitinib [11]
(Vizimpro®) targeting EGFR, or acalabrutinib [12] (Calquence®) and
ibrutinib [13] (Imbruvica®) targeting BTK.
TCI molecules consist of two main parts: in addition to the
noncovalent drug-like scaffold, they are equipped with an appro-
priate electrophilic warhead [14e18]. In addition to the optimiza-
tion of noncovalent interactions, rational design of the warhead
moiety is of utmost importance [19,20]. The different location and
surroundings of the targeted cysteine influence its reactivity and
accessibility through changes in the protonation state, the spatial
arrangement of the reacting groups, the geometries of the transi-
tion states, the intermediates and the product of the covalent bond-
forming reaction [21]. These factors distinguish between the la-
beling properties of the cysteine residues. In fact, recent proteomic
studies have suggested that cysteine reactivity might bess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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appropriate warhead first requires assessment of the reactivity and
accessibility of the targeted cysteine [23]. The available experi-
mental methodologies to evaluate the tractability of cysteines are
using activity-based protein profiling (ABPP) [22,24,25] These are
all proteomic-level screening techniques performed on living cells
and require a powerful MS/MS platform. Even with this high-end
instrumentation, other factors, such as the diversity of targets, in-
fluence of unknown cellular proteins, and low abundance of the
modified protein make the detection of protein adducts in a com-
plex matrix challenging. The only alternatives are computational
techniques that have been used for the identification and charac-
terization of reactive cysteines [26e32]. Compilation of targetable
cysteines across the human kinome has inspired various research
groups, and attempts have been carried out using X-ray based [33],
sequence-based [34] and interaction fingerprint-based methodol-
ogies [27]. In addition to their position and accessibility, the pro-
tonation state of the cysteine thiol has a major influence on its
reactivity. Recent articles evaluating cysteine pKa values include a
statistical analysis by Zhang et al. [29] and a sophisticated
computational study by Awoonor-Williams and Rowley [26]. These
studies suggest that the targeted cysteines should have a relatively
low pKa value, so that the more nucleophilic thiolate form will
dominate [35].
Here we introduce a ligand-based technique for mapping
cysteine reactivity and accessibility by screening a set of covalent
fragments with diverse reactivity. Furthermore, the best perform-
ing warheads might serve as a viable starting point for fragment-
based optimization aiming to develop targeted covalent inhibitors
[36,37]. Although several comparative studies have been published
onwarhead reactivity [38e40], our library of warheads equipped to
the same scaffold represents a unique opportunity for the efficient
integration of warhead optimization into the covalent drug devel-
opment process. In our preliminary study we found that a smaller
proof-of-concept library covered a wide range of reactivity in sur-
rogate assays [41]. Screening of the extended library described
herein against protein kinases provides experimental reactivity and
accessibility data of the targeted cysteines.
2. Results and discussion
2.1. Design and characterization of the covalent fragment library
A ligand-based cysteine mapping technique requires a carefully
designed toolbox of covalent probes. Thus, first we intended to
compile a preconceived set of fragments suitable for the assess-
ment of the targeted cysteines via protein-level biochemical assays.
Focusing on the covalent action we kept the noncovalent moiety
small and apolar to minimize the noncovalent interaction contri-
bution to fragment binding [42]. Thus, we chose the 3,5-
bis(trifluoromethyl)phenyl scaffold, which showed no interfer-
ence with any of the assay components, was stable in the assay
conditions, provided easy detection by HPLC-MS and 19F NMR, and
furthermore, the electron withdrawing character of the tri-
fluoromethyl substituents could activate the electrophilic center of
the warheads. In total, we selected 24 covalent fragments (1-24)
(Fig. 1) representing different levels of size and complexity. In
addition, the flexibility of the warheads had also a large variety
depending on the double or triple bonds, the direct CeC connection
or binding through an amide bond or a methylene group to the
aromatic ring. The library members or their corresponding in-
termediates were obtained from commercial sources or by syn-
thesis (for the synthesis details see Supplementary Methods).
Assessing the electrophilic character of the probes, we calcu-
lated the local electrophilicity index [43]. These data showed that2
the library covers a wide range of theoretical electrophilicity (local
EPI values of 0.148 for the least and of 0.581 for the most elec-
trophilic probe). For the experimental confirmation, we have tested
the probe library in a GSH-reactivity assay [39,44] (Supplementary
Table S1). Nine fragments showed weak reactivity (kGSH < 0.01 h1
for 7, 8, 13e16, 18, 19 and 24), seven fragments had moderate
reactivity (0.01 < kGSH < 0.5 h1 for 1, 3, 9, 17, 21, 22, 23) and
additional seven fragments (2, 5, 6, 10, 11, 12, 20) were found to be
highly reactive in the GSH assay. There were some warheads that
showed similar reactivities (e.g. 8, 14, 18 and 1, 17); however, their
labeling mechanisms are quite different and therefore either might
be preferred at certain cysteine targets [21]. The cysteine selectivity
of the applied covalent fragments was confirmed in our recently
introduced oligopeptide assay [44]. As cysteine reactivity can be
highly influenced by its environment in a particular protein, the
broad spectrum of chemical reactivities and labeling mechanisms
might significantly support the mapping efficiency of the probe
library. Thus, this specific covalent fragment library could be a
useful chemical toolbox for experimental mapping of the reactivity
and accessibility of targeted cysteines.
2.2. Mapping the reactivity of kinase cysteines
As differences in the active sites of kinases influence the reac-
tivity and accessibility of the targeted cysteines, we proposed to
map the cysteine reactivity profile of main kinase families. The
target kinases were selected as therapeutically significant and
already covalently targeted members of the kinase phylogenetic
tree that provides good coverage of the human kinome based on
their inferred evolutionary relationships (Fig. 2) [45].
Taking into account the availability of covalently tractable
cysteine residues [27], four kinases were picked up from different
branches. We selected BTK from the TK (tyrosine kinase) branch,
ERK2 from the CMGC (containing the families CDK, MAPK, GSK3
and CLK) branch, RSK2 from the AGC (containing the families PKA,
PKG and PKC) branch andMAP2K6 from the STE (yeast sterile 7-,11-
and 20-homologous kinases) branch. Known covalent inhibitors of
the selected kinases are summarized in Supplementary
Information Table S2 according to their major warhead chemo-
types. The mapping library (1e24) was screened on the four ki-
nases. Kinase activity was assessed at a concentration of 100 mM of
each fragment with the selected kinases (BTK, ERK2, RSK2,
MAP2K6) after 60 min of incubation in duplicate. The results of the
activity profiling are shown as radar plots in Fig. 3 (for detailed
results, see Supplementary Table S3).
As expected, different targets showed different activity profile.
Particularly, of the 24 covalent fragments, 5, 6, 12 and 23 displayed
high activities (70%) across the whole panel, while consistently
low inhibition values (<50%) were determined for 3, 9,14,15, 16,18
and 24. The remaining thirteen fragments represent the discrimi-
natory power of the various warhead chemistries among the ki-
nases in the panel. Some have a clear preference for one of the
kinases, such as 13 (RSK2) or 19 (BTK), while others display various
patterns among the panel, such as 8 (RSK2) or 22 (active against all
but ERK2). It has been observed that the intrinsic reactivity over-
came the impact of the warhead size. For instance, the bulky mal-
eimides (5 and 6), although they are among the largest warheads in
this study, performed exceedingly on all investigated kinases. On
the contrary, the 12 isothiocyanate, which is less influenced by
steric factors, also performed remarkably well. In spite of these
examples, the sterically least hindered warheads, such as the sty-
rene (13), the acetylene (14) or the nitrile (15), but also the larger
Boc-protected hydrazine (16) did not show significant inhibition of
any of the kinases. However, the smallest warhead, fluorine (22)
showed quite diverse reactivity profile, while the second smallest
Fig. 1. Covalent fragment probes 1e24.
Fig. 2. Kinases that contain at least one targetable cysteine and are available for testing
with the selected enzyme activity assay (Z0-LYTE, Life Technologies), indicated (with
red dots) on the kinase phylogenetic tree. Black circles show kinases involved in the
mapping. The figure was prepared with the Kinome Render program [46]. (For inter-
pretation of the references to color in this figure legend, the reader is referred to the
Web version of this article.)
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kinases. Moreover, it seems that the biological activity was mainly
influenced by the warhead chemistry and the common scaffold
provided low contribution to the inhibition potency. This is
underlined by the comparison of the appropriate compounds: 1, 5,
14 and 24. Compound 1 is equipped with a widely used warhead3
(acrylamide) that shows specific inhibition against BTK, while it has
no significant biological activity on the other 3 kinase targets
(ERK2, RSK2 and MAP2K6). This suggests that not only reactivity
differences but selectivity issues can be addressed directly to the
warhead chemistry. In addition, fragment 5 equipped with a highly
reactive maleimide warheade used extensively in protein labelling
studies e inhibit all of the targets. Finally, fragments 14 and 24
carrying the acetylene and the aldehyde function, respectively, that
have limited cysteine-reactivity [17,47] did not show significant
inhibition against any of the targets, however it has the same
scaffold as used for all the library members. We found that
changing the chlorine to bromine in thewarhead, however, leads to
increased inhibition against BTK (39% with 16 / 94% with 17),
suggesting that small changes can influence the activity signifi-
cantly while keeping the noncovalent core unchanged. It is
important to note that different warhead chemistries represent
various degrees of reactivity and different transition state/product
geometries, while the location and the environment of the cyste-
ines adds another layer of diversity that also influences the overall
results.2.3. Retrospective validation on JAK3
JAK3 was chosen as potential target for retrospective validation.
Noteworthy, the active site of the JAK family is highly conserved,
thus selectively achieving ATP-competitive inhibition is chal-
lenging. However, a non-conserved cysteine (Cys909) residue is
located near the ATP binding site of JAK3, while no vulnerable
nucleophilic residue can be found at the active sites of other JAK-
subtypes. This unique feature makes JAK3 tractable and alluring
for covalent inhibitor programs [48e52]. Sequence analysis
(Supplementary Table S4) showed that BTK has the most similar
active site to JAK3. As a first step of validation, we screened the
mapping library against JAK3 and compared the reactivity profile to
that of BTK (Fig. 4 and Supplementary Table S3). We found that the
calculated reactivity and accessibility of the JAK3 active site
cysteine (Supplementary Table S4) was by far the closest to BTK
based on the calculated pKa values and H-bond contributions, as
well as the accessibility (solvent-exposed surface area, SASA) of the
Fig. 3. Radar plots of the inhibitory activities of the covalent fragment library (1e24).
Fig. 4. Radar plot of the inhibitory activity of the covalent fragment library against
JAK3 together with the warheads chosen for further analysis.
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tivity mapping are in line with the sequential and structural simi-
larity of the two kinases. Upon analyzing the inhibition profiles of
JAK3 and BTK, after excluding the promiscuous warheads, we
concluded that the warheads of probes 1, 4, 17 and 19 (acrylamide,
cyano-acrylamide, chloroacetamide and 2-bromopropanamide,
respectively) could provide the best affinity and selectivity for JAK3
compounds (Fig. 4). Covalent labeling of the Cys909 residue with
the 1 and 17 probes was confirmed by MS/MS studies after diges-
tion of the incubated protein samples (Supplementary Fig. S1).
Next, we challenged our warhead selection strategy by using the
chosen warheads on a well-established hinge binder scaffold, 4-
phenyl-pyrrolo[2,3-d]pyrimidine that is utilized by many kinase
inhibitors [49,52e54]. This scaffold is providing a synthetically
feasible option for warhead optimization. The synthesis of the
compounds was carried out in two main steps starting with the
preparation of the appropriate intermediates (25e26, Scheme 1a)
directly prepared by the Suzuki coupling of 4-chloro-1H-pyrrolo
[2,3-d]pyrimidine (27) and the properly substituted phenylboronic
acid (28e29) [52]. Cyano-acrylamide 30 was derived from 25
aldehyde by Knoevenagel condensation [55] (Scheme 1b), while
compounds 31 and 32 were synthesized from 26 amine by the
corresponding acylation (Scheme 1c). In addition, to confirm the
significant contribution of the covalent interaction to the inhibition,
we decided to investigate 32 noncovalent control containing the
same scaffold equippedwith an acetamide functional group instead
of an electrophilic warhead.
Introducing the selected warheads from fragments 1 and 17 led
to known covalent JAK3 inhibitors 33 and 34 (Scheme 1d) having4
low nanomolar or even subnanomolar IC50 (0.77 and 1.02 nM,
respectively) [54]. Notably, 33 acrylamide was confirmed to bind
JAK3 ATP-site covalently through Cys909 [52]. The 30 cyano-
acrylamide derived from fragment 4 showed some activity
against MAP2K6 and RSK2 [56] (281 and 399 nM, respectively) but
blocked JAK3 more effectively (IC50 ¼ 55.9 nM). Finally, using the
haloacetamide warhead of fragment 19 resulted in a novel covalent
JAK3 inhibitor (31) with an IC50 ¼ 10.6 nM (Scheme 1).
Using the most effective warheads identified by screening our
probe library we confirmed that noncovalent interactions are not
solely responsible for the selectivity and specificity of covalent in-
hibitors. Compounds 30,31,33 and 34 differ from 32 only in the
presence of an electrophilic warhead suggesting that the covalent
interaction contributes significantly to the observed activity
(IC50 ¼ 832 nM for 32 and 0.77e55.9 nM for 30, 31, 33, 34).
Furthermore, introducing the selected warheads to a hinge binder
scaffold, we successfully retrieved already known JAK3 inhibitors
(33 and 34) and identified two additional compounds with low-
nanomolar activity (30 and 31). Our results suggest that the map-
ping of active site cysteines in other kinase targets provides useful
information on the reactivity and accessibility of the targeted res-
idue and could help in finding the appropriate warheads for tar-
geted covalent inhibitors.
2.4. Prospective validation on MELK
Promising results obtained during the retrospective validation
of the cysteinemapping protocol prompted us to apply this strategy
prospectively to identify other potential targets for covalent drug
discovery programs. For this purpose, we chose MELK kinase which
has recently been emerged as an active research target in various
oncology-related indications [57e61]. Noteworthy, to the best of
our knowledge, no validated covalent inhibitor for MELK has been
disclosed yet. Therefore, we decided to analyze the tractability of
MELK applying the ligand-based mapping technique presented
herein. The activity profile is shown in Fig. 5a (for detailed results
see Supplementary Table S3) that suggested three suitable war-
heads for covalent targeting of MELK including the 4 cyano-
acrylamide, the 11 isothiocyanate and the 20 bromoacetophenone
warheads. Motivated by the high fluorine content of the probes,
covalent labelling was confirmed by 19F NMR measurements
(Fig. 5b). In fact, fragments have been incubated with the isolated
MELK protein, and the change in the 19F NMR shifts has been fol-
lowed for 24 h. Comparing the spectra with the protein-free
reference, probes 4, 11 and 20 were proven to label covalently
MELK (Supplementary Fig. S2) with the labelling efficiency of 97%,
30% and 60%, respectively. We have chosen the most potent
warhead chemotype (particularly the cyano-acrylamide, 4), and
together with the general hinge binder scaffold, we tested the
previously synthesized analogue (30) against MELK (Fig. 5c).
Measuring the activity on MELK we found that 30 is an effective
inhibitor (IC50 ¼ 25.5 nM, Fig. 5c), while the noncovalent control 32
Scheme 1. Synthetic routes to the designed covalent JAK3 inhibitors: (a) Key intermediates 25e26 were prepared by Suzuki coupling; (b) synthesis of cyano-acrylamide 30; and (c)
synthesis of amides 31e32. d) Covalent JAK3 inhibitors (33, 34) retrieved retrospectively.
Fig. 5. a) Radar plot of the inhibitory activity of the covalent fragment library against MELK. b) Covalent binding of probe 4 confirmed by 19F NMR. c) MELK inhibitory activity of
compound 30 and its noncovalent control (32). d) Proposed binding mode of compound 30 at the ATP site of MELK.
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magnitude difference between the IC50 data suggests the signifi-
cant contribution of the covalent interaction. Although the exact
site of labelling could not be identified by preliminary MS/MS ex-
periments, computational analysis identified two tractable cyste-
ines [27]. One of these residues are located in the hinge region at
position Hinge-2 (Cys89), the other sits in the hydrophobic sub-
pocket at position Beta-4-2 (Cys70). Covalent docking of 30 to the
ATP site of MELK suggests the latter as the potential site of labelling
(Fig. 5d).5
3. Conclusion
Here we provided a novel and readily available ligand based
alternative for the experimental characterization of tractable cys-
teines and target-specific selection of electrophilic warheads. We
showed that screening a small library of electrophiles provides
reactivity and accessibility information on targeted cysteines,
which might be useful identifying tractable targets for covalent
inhibition. Our approach selects proper warheads for noncovalent
kinase inhibitor scaffolds turning them into covalent inhibitors. The
approach has been first challenged in a retrospective validation
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warheads and then equipped these to a known hinge binder core
fragment (4-phenyl-pyrrolo[2,3-d]pyrimidine). This design strat-
egy resulted in four covalent inhibitors, two known compounds
were retrieved and two further compounds were identified as
novel covalent JAK3 inhibitors. The usefulness of our cysteine
profiling strategy has been confirmed prospectively on MELK as a
target. Screening the probe library suggested three potential war-
heads and their covalent binding was subsequently confirmed by
19F NMRmeasurements. Using themost effective cyano-acrylamide
warhead, we identified a novel covalent MELK inhibitor with low-
nanomolar activity. Based on the success of both the retrospective
and prospective application we suggest screening the probe library
to evaluate the accessibility and reactivity of targeted cysteines in
protein kinases and to select potential warheads for developing
novel covalent inhibitors. The probe library is available in physical
form from the authors upon request. Considering the significant
efforts invested to discover new warhead chemotypes, we plan to
include these newwarheads in the next edition of the probe library.
4. Experimental section
4.1. Instruments
1H NMR spectra were recorded in DMSO‑d6 or CDCl3 solution at
room temperature, on a Varian Unity Inova 500 spectrometer
(500 MHz for 1H NMR spectra), with the deuterium signal of the
solvent as the lock and TMS as the internal standard. Chemical
shifts (d) and coupling constants (J) are given in ppm and Hz,
respectively.
19F NMR measurements were performed using a 500 MHz
Bruker Avance NEO spectrometer equipped with a 5 mm Prodigy
BBO probe with z-gradient at 298 K.
HPLC-MS measurements were performed using a Shimadzu
LCMS-2020 device equipped with a Reprospher 100C18 (5 mm;
100  3mm) column and positive-negative double ion source
(DUIS±) with a quadrupole MS analyzator in a range of 50e1000m/
z. Sample was eluted with gradient elution using eluent A (10 mM
ammonium formate in water:acetonitrile 19:1) and eluent B
(10 mM ammonium formate in water:acetonitrile 1:4). Flow rate
was set to 1 ml/min. The initial conditionwas 0% B eluent, followed
by a linear gradient to 100% B eluent by 1 min, from 1 to 3.5 min
100% B eluent was retained; and from 3.5 to 4.5 min back to initial
condition with 5% B eluent and retained to 5 min. The column
temperature was kept at room temperature and the injection vol-
ume was 10 ml. Purity of compounds was assessed by HPLC with UV
detection at 215 nm; all tested compounds were >95% pure.
A Sciex 6500 QTRAP triple quadrupole e linear ion trap mass
spectrometer, equipped with a Turbo V Source in electrospray
mode (Sciex, CA, USA) and a PerkinElmer Series 200 micro LC
system (Massachusetts, USA) consisting of binary pump and an
autosampler was used for LCeMS/MS analysis. Data acquisition and
processing were performed using Analyst software version 1.6.2
(AB Sciex Instruments, CA, USA). Chromatographic separation was
achieved by Purospher STAR RP-18 endcapped (50 mm  2,1 mm,
3 mm) LiChocart® 55-2 HPLC Cartridge. Sample was eluted with
gradient elution using solvent A (0.1% formic acid in water) and
solvent B (0.1% formic acid in acetonitrile). Flow rate was set to
0.5 ml/min. The initial condition was 5% B for 2 min, followed by a
linear gradient to 95% B by 6 min, from 6 to 8 min 95% B was
retained; and from 8 to 8.5 min back to initial condition with 5%
eluent B and retained to 14.5 min. The column temperature was
kept at room temperature and the injection volume was 10 ml. Ni-
trogen was used as the nebulizer gas (GS1), heater gas (GS2), and
curtain gas with the optimum values set at 35, 45 and 45 (arbitrary6
units), respectively. The source temperature was 450 C and the ion
spray voltage set at 5000 V. Declustering potential value was set to
150 V.
4.2. Local electrophilicity (local EPI) calculations
Full geometry optimizations and frequency analyses of DFT
calculations were carried out in implicit aqueous solution at the
B3LYP/6e311þþG(2d,2p) level of theory using the Gaussian 09
program package [62]. Chemical descriptors were calculated from
the optimized structures as described in the literature [43,63].
4.3. GSH reactivity assay
For thiol reactivity determination recently published assay was
applied [41,44].
4.4. Oligopeptide selectivity assay
For residue selectivity determination, a recently puplished
nonapeptide assay was applied [44].
4.5. Kinase activity assays
Fragments 1e24 were tested at 100 mM in duplicate data points
with the Z0-LYTE kinase inhibition assay (Life Technologies). The
assay employs a fluorescence-based format and is based on the
different sensitivity of phosphorylated and non-phosphorylated
peptides to proteolytic cleavage. A suitable peptide substrate is
labeled with two fluorophores, forming a FRET pair. After 1 h pre-
incubation with the test compounds the peptide substrate is added
and incubating the kinase þ peptide þ test compound mixture for
an additional hour, a development reaction is carried out. Any
peptide that was not phosphorylated by the kinase is cleaved,
disrupting the resonance energy transfer between the FRET pair.
The reaction progress is quantified based on the ratio of the
detected emission at 445 nm (coumarin) and 520 nm (fluorescein),
i.e. the ratio of cleaved vs intact peptide. More detailed description
of the assay is available on the website of Life Technologies [64].
IC50 values for 30-32 compounds were determined from 10 points
titration measurements after the same preincubation protocol
described above using the SelectScreen™ Biochemical Kinase
Profiling Service available at Life Technologies.
4.6. JAK3 proteomics MS/MS
To 50 mL of the 12 mM JAK3 stock solution in 20mMTris at pH 8.0
with 150 mM NaCl and 2 mM MnCl2, 1 mL of the covalent probes
were added from a 100 mM DMSO stock solution, then the mixture
was incubated at room temperature for 120min. After the labelling,
the mixture was digested immediately. Briefly 40e50 mL of the
sample and 10 mL 0.2% (w/v) RapiGest SF (Waters, Milford, USA)
solution buffered with 50 mM ammonium bicarbonate were mixed
(pH ¼ 7.8) and 3.3 mL of 45 mM DTT in 100 mM NH4HCO3 were
added and kept at 37.5 C for 30 min. After cooling the sample to
room temperature, 4.2 mL of 100 mM iodoacetamide in 100 mM
NH4HCO3 were added and placed in the dark in room temperature
for 30 min. The reduced and alkylated proteinwas then digested by
10 mL (1 mg/mL) trypsin (the enzyme-to-protein ratio was 1: 10)
(Sigma, St Louis, MO, USA). The sample was incubated at 37 C for
overnight. To degrade the surfactant, 7 mL of formic acid (500 mM)
solution was added to the digested JAK3 sample and it was incu-
bated at 37 C for 45 min. For LC-MS analysis, the acid treated
sample was centrifuged for 5 min at 13 000 rpm. QTRAP 6500 triple
quadruple e linear ion trap mass spectrometer, equipped with a
L. Petri, A. Egyed, D. Bajusz et al. European Journal of Medicinal Chemistry 207 (2020) 112836Turbo V source in electrospray mode (AB Sciex, CA, USA) and a
PerkinElmer Series 200 micro LC system (Massachusetts, USA) was
used for LC-MS/MS analysis. Data acquisition and processing were
performed using Analyst software version 1.6.2 (AB Sciex In-
struments, CA, USA). Chromatographic separation was achieved by
using the Vydac 218 TP52 Protein & Peptide C18 column
(250 mm  2.1 mm, 5 mm). The sample was eluted with a gradient
of solvent A (0.1% formic acid in water) and solvent B (0.1% formic
acid in ACN). The flow rate was set to 0.2 mL min1. The initial
conditions for separation were 5% B for 7 min, followed by a linear
gradient to 90% B by 53 min, from 60 to 63 min 90% B is retained;
from 64 to 65 min back to the initial conditions with 5% eluent B
retained to 70 min. The injection volume was 10 mL (300 pmol on
the column). Information Dependent Acquisiton (IDA) LC-MS/MS
experiment was used to identify the modified tryptic JAK3 pep-
tide fragments. Enhanced MS scan (EMS) was applied as survey
scan and enhanced product ion (EPI) was the dependent scan. The
collision energy in EPI experiments was set to rolling collision en-
ergy mode, where the actual value was set on the basis of the mass
and charge state of the selected ion. Further IDA criteria: ions
greater than: 400.000 m/z, which exceeds 106 counts, exclude
former target ions for 30 s after 2 occurrences. In EMS and in EPI
mode the scan rate was 1000 Da/s as well. Nitrogenwas used as the
nebulizer gas (GS1), heater gas (GS2), and curtain gas with the
optimum values set at 50, 40 and 40 (arbitrary units). The source
temperature was 350 C and the ion spray voltage set at 5000 V.
Declustering potential value was set to 150 V. GPMAW 4.2. software
and ProteinProspector (http://prospector.ucsf.edu/prospector/
mshome.htm) was used to analyze the large number of MS/MS
spectra and identify the modified tryptic JAK3 peptides.4.7. NMR measurements for MELK
The MELK protein and the ligands were dissolved in a 10% (v/v)
D2O and H2O mixture containing 20 mM Tris buffer (pH 7.6),
150 mM NaCl and 10% glycerine. For the 19F measurements, the
MELK and the BTF ligands concentrations were 20 and 40 mM,
respectively. As a reference, 19F experiments were also performed
without the target, containing the ligand species alone. All 19F NMR
spectrawere recorded in the range of F100 to 0 ppm. A delay time
(D1) of 1 s was adopted. To maximize sensitivity, 256 scans were
collected into 131072 data points. The Bruker pulse program, zg,
was used with a receiver gain (RG) of 54. All 19F NMR spectra were
phased and baseline corrected using the Topspin 4.2 software
package (Bruker BioSpin, Rheinstetten, Germany).4.8. Covalent docking
The binding mode of compound 30 in the binding site of MELK
(PDB structure 5IH9 [65]) was modeled with the Covdockworkflow
of the Schr€odinger Suite in the more precise Pose Prediction mode
[66]. Briefly, the workflow consists of (i) non-covalent docking to
the binding site with Glide [67], (ii) formation of the covalent bond
between the ligand and the reactive residue, if the geometry of the
non-covalent binding pose permits, (iii) minimization of the
resulting covalent complex with Prime [68], and (iv) re-scoring the
minimized complex with Glide. Five poses were saved and visually
assessed both for Cys70 and for Cys89, with the one in Fig. 5D
proposed as the most plausible binding mode (based on the
favorable H-bonding pattern and closeness of the core scaffold to
the hinge region).7
4.9. Synthesis
4.9.1. General procedure of Suzuki coupling [52]
To a solution of 4-chloro-7H-pyrrolo[2,3-d]pyrimidine (1 eq.)
and boronic acid (1.3 eq.) in dioxane/H2O (5:1), K2CO3 (3 eq.) and
Pd(PPh3)4 (0,1 eq.) were added under Ar. Themixturewas heated to
110 C for 16 h. The mixture was concentrated and water and DCM
were added. The resulting mixture was filtered and the filtrate
extractedwith CH2Cl2 (3). The organic layer dried over anhydrous
Na2SO4. The solvent was removed and the crude material purified
by reverse phase chromatography (H2O/CH3CN ¼ 10e100%).
4.9.2. 3-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)benzaldehyde (25)
4-Chloro-7H-pyrrolo[2,3-d]pyrimidine (27) (1.5 g; 9.76 mmol),
(3-formylphenyl)boronic acid (28) (1.74 g; 11.7 mmol), K2CO3 (4.1 g;
29.4 mmol), Pd(PPh3)4 (1.25 g; 0.97 mmol) in dioxane/H2O (5:1)
54 ml, 1.27 g (58%) yellow solid was obtained [1]. 1H NMR
(500 MHz, DMSO‑d6) d 12.33 (s, 1H, NH), 10.17 (s, 1H, CHO), 8.89 (s,
1H, ArH), 8.70 (s, 1H, ArH), 8.50 (d, J ¼ 7.7 Hz, 1H, ArH), 8.06 (d,
J ¼ 7.6 Hz, 1H, ArH), 7.81 (t, J ¼ 7.7 Hz, 1H, ArH), 7.71 (d, J ¼ 1.6 Hz,
1H, ArH), 6.96 (d, J ¼ 3.2 Hz, 1H, ArH) ppm. 13C NMR (126 MHz
DMSO‑d6) d 193.62, 154.49, 153.21, 151.35, 139.19, 137.16, 134.61,
130.60, 130.28, 130.24, 128.66, 115.03, 100.22 ppm. HRMS (ESI):
(M þ H)þ calcd. for C13H9N3Oþ, 224.0823; found, 224.0819.
4.9.3. 3-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)aniline (26) [52]
To a solution of 4-chloro-7H-pyrrolo[2,3-d]pyrimidine (27)
(1.5 g, 9.76 mmol) and (3-aminophenyl)boronic acid (29) (1.8 g,
11.7 mmol) in 54 mL dioxane/H2O (5:1), K2CO3 (4.1 g, 29.4 mmol)
and Pd(PPh3)4 (1.125 g, 0.97 mmol) were added under Ar. The
mixture was heated to 110 C for 16 h. The mixture was concen-
trated and water and DCM were added. The resulting mixture was
filtered and the filtrate extracted with CH2Cl2 (3 ). The organic
layer was dried over anhydrous Na2SO4. The solvent was removed
and the crude material purified by reverse phase chromatography
(H2O/CH3CN ¼ 10e100%). 610 mg (30%) yellow solid was obtained.
1H NMR (500 MHz, DMSO‑d6) d 13.06 (s, 1H, NH), 9.02 (s, 1H, ArH),
8.11 (s, 1H), 8.05 (d, J¼ 7.8 Hz, 1H, ArH), 7.93 (d, J¼ 2.7 Hz, 1H, ArH),
7.70 (t, J ¼ 7.9 Hz, 1H, ArH), 7.56 (d, J ¼ 8.0 Hz, 1H, ArH), 7.14 (d,




(223 mg, 1.0 mmol) and 2-cyanoacetamide (35) (126 mg, 1.5 mmol)
were dissolved in methanol (10 mL). Catalytic NaOH (1 mg, 1%) was
added, and the reaction was stirred at 45 C for 4 h. The reaction
was concentrated under vacuum. The residue was purified on
reversed phase column chromatography with a mixture of water
and acetonitrile as eluent. The product was obtained as colorless oil
(58 mg, 20%). 1H NMR (500MHz, DMSO‑d6) d 12.32 (s, 1H, NH), 8.85
(s, 1H, ArH), 8.70 (s, 1H, ArH), 8.36 (d, J ¼ 7.8 Hz, 1H, ArH), 8.33 (s,
1H, eCH ¼ ), 8.06 (d, J ¼ 7.6 Hz, 1H, ArH), 7.95 (s, 1H, C(O)NH2), 7.76
(m, 2H, ArH and C(O)NH2), 7.68 (d, J ¼ 3.3 Hz, 1H, ArH), 7.01 (d,
J ¼ 3.3 Hz, 1H, ArH) ppm. 13C NMR (125 MHz, DMSO‑d6) d 172.48,
163.17, 154.63, 153.18, 150.75, 139.21, 133.00, 132.54, 131.80, 130.28,
130.07, 128.57, 116.84, 115.00, 107.99, 100.26 ppm. HRMS (ESI):
(M þ H)þ calcd. for C16H11N5Oþ, 290.1041; found, 290.1039.
4.9.5. N-(3-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)-2-
bromopropanamide (31)
To a solution of 3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)aniline (26)
(210 mg; 1.0 mmol) in 3 ml DCM at 0 C TEA (417 ml; 3.0 mmol) was
added followed by the dropwise addition of 2-bromopropanoil
chloride (36) (111 ml; 1.1 mmol). After addition, the mixture was
L. Petri, A. Egyed, D. Bajusz et al. European Journal of Medicinal Chemistry 207 (2020) 112836stirred at room temperature for 1 h. The solvent was removed, and
the crude material purified by flash chromatography (CH2Cl2/
MeOH ¼ 1e5%) to give 175 mg (50%) product as yellow solid. 1H
NMR (500MHz, DMSO‑d6) d 12.28 (s,1H, NH), 10.55 (s, 1H, C(O)NH),
8.84 (s, 1H, ArH), 8.57 (s, 1H, ArH), 7.94 (d, J ¼ 7.6 Hz, 1H, ArH), 7.75
(d, J¼ 7.3 Hz, 1H, ArH), 7.70 (s, 1H, ArH), 7.56 (d, J¼ 7.9 Hz, 1H, ArH),
6.95 (s, 1H, ArH), 4.79e4.68 (m, 1H, CHBr), 1.80 (d, J ¼ 6.6 Hz, 2H,
CH3), 1.66 (d, J ¼ 6.6 Hz, 1H, CH3) 13C NMR (125 MHz, DMSO‑d6)
d 168.21, 155.20, 153.15, 151.07, 139.43, 139.34, 129.85, 128.47,
124.28,121.23,119.95,114.90,100.46, 44.90, 21.83 ppm. HRMS (ESI):
(M þ H)þ calcd. for C15H13BrN4Oþ, 345.0350; found, 345.0348.
4.9.6. N-(3-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)acetamide
(32)
3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)aniline (26) (210 mg,
1.0 mmol) was stirred under Ar atmosphere in 5 mL acetic anhy-
dride (37) at RT overnight. The reaction mixture was concentrated
under vacuum and the crude product was further purified on
reversed phase column chromatography with a mixture of water
and acetonitrile as eluent. Finally, 32was obtained as black powder
(43mg,17%). 1H NMR (500MHz, DMSO‑d6) d 12.22 (s, 1H, NH), 10.13
(s, 1H, C(O)NH), 8.81 (s, 1H, ArH), 8.50 (s, 1H, ArH), 7.85 (d,
J ¼ 7.8 Hz, 1H, ArH), 7.72 (d, J ¼ 8.1 Hz, 1H, ArH), 7.65 (d, J ¼ 2.2 Hz,
1H, ArH), 7.48 (t, J ¼ 7.9 Hz, 1H, ArH), 6.91 (d, J ¼ 2.7 Hz, 1H, ArH),
2.08 (s, 3H, CH3) ppm. 13C NMR (500 MHz, DMSO‑d6) d 168.99,
155.66, 153.09, 151.25, 140.10, 138.69, 129.59, 128.12, 123.46, 120.82,
119.62, 114.89, 100.42, 24.50 ppm. HRMS (ESI): (M þ H)þ calcd. for
C14H12N4Oþ, 253.1089; found, 253.1085.
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